Crystal Lake, Illinois, April 30, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year.
First Quarter 2026 Highlights
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
- Reported sales increased 11% and core sales were flat
- Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12
- Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency
- Adjusted EBITDA margin was 2% compared to 20.7% in the prior year
- Returned $131 million to shareholders through share repurchases and dividends
- Gael Touya named Aptar’s next CEO effective September 1, 2026
“Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP‑1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications,” said Stephan B. Tanda, Aptar President and CEO.
Download the full press release here.
